SALT LAKE CITY, Feb. 28, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming 89th annual American Mosquito Control Association (AMCA) conference on February 28-March 3 in Reno, Nevada.
The AMCA Annual Meeting is listed as the premier education and networking event for researchers, educators, vector control professionals, industry representatives, and students in mosquito control. Co-Dx believes the event will provide opportunities for Company representatives to introduce Co-Diagnostics vector control PCR products to a wide array of professionals in the field, following a year where the Company saw growth in terms of both new laboratory installations and reagent purchases from existing customers.
To learn more about the conference, including registration details, please visit https://www.eventscribe.net/2023/AMCA. Attendees interested in learning more about the Company and its products, including its suite of Vector Smart™ tests and other equipment, are invited to visit Booth #107.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
Last Trade: | US$1.07 |
Daily Change: | -0.01 -0.93 |
Daily Volume: | 67,023 |
Market Cap: | US$34.140M |
November 07, 2024 September 05, 2024 August 08, 2024 July 02, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB